Qiagen N.V. QGEN
Set alert
As of Nov 3, 12:13 PM ET
- YTD
- +11.85%
- 1 year
- +10.11%
- Open
- 50.41
- Prev close
- 50.35
- Mkt cap
- 10.39B
- Vol
- 4.97M
- Avg vol
- 3.62M
- EPS
- 1.97
- P/E
- 25.54
- Div yield
- 0.70%
More statistics
- Low
- 50.26
- High
- 50.41
- Forward P/E
- 19.26
- Beta
- 0.56
- Short ratio
- 3.34
- Inst. own
- 79.43%
- Dividend
- 0.35
- Ex-div date
- Jul 6, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 45.11
- 200-d avg
- 42.59
- 1y target
- 49.02
5m chart
Built from the cached five-day intraday bars.
Events in this range
- Oct 28, 2026Downgrade: Barclays · Overweight → Equal-Weight
Signals (84)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 3, 11:20 AM | 53 minutes ago |
| SMA: Bearish | Nov 3, 11:10 AM | 1 hour ago |
| MACD: Buy Signal | Nov 3, 10:45 AM | 1 hour ago |
| SMA: Bullish | Nov 3, 10:35 AM | 1 hour ago |
| SMA: Bullish | Nov 3, 10:05 AM | 2 hours ago |
| MACD: Sell Signal | Nov 3, 9:55 AM | 2 hours ago |
| SMA: Bearish | Nov 3, 9:50 AM | 2 hours ago |
| SMA: Bullish | Nov 3, 9:45 AM | 2 hours ago |
| SMA: Bullish | Nov 3, 9:45 AM | 2 hours ago |
| MACD: Buy Signal | Nov 3, 9:45 AM | 2 hours ago |
| SMA: Bearish | Nov 3, 9:40 AM | 2 hours ago |
| SMA: Bearish | Nov 3, 9:40 AM | 2 hours ago |
| MACD: Sell Signal | Nov 3, 9:40 AM | 2 hours ago |
| SMA: Bullish | Nov 3, 9:30 AM | 2 hours ago |
| SMA: Bullish | Nov 3, 9:30 AM | 2 hours ago |
| SMA: Bearish | Nov 2, 3:55 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 3:55 PM | 20 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 3:10 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 3:05 PM | 21 hours ago |
Newest 20 of 84.
Key statistics
- Market cap
- 10.39B
- Enterprise value
- 11.23B
- Trailing P/E
- 25.55
- Forward P/E
- 19.26
- PEG ratio
- 1.34
- Price / sales
- 4.95
- Price / book
- 3.10
- EPS (TTM)
- 1.97
- Beta
- 0.56
- Dividend yield
- 0.70%
- Payout ratio
- 17.79%
- Profit margin
- 19.49%
- Revenue (TTM)
- 2.10B
- Revenue growth
- 0.30%
- Free cash flow
- 372.86M
- Total cash
- 793.50M
- Total debt
- 1.65B
- Return on equity
- 11.93%
- Shares outstanding
- 206.50M
- Short % of float
- 3.95%
- 50-day average
- 45.11
- 200-day average
- 42.59
Analyst view
Consensus: hold
- Target (low)
- 40.00
- Target (mean)
- 49.02
- Target (high)
- 53.00
- Strong buy1
- Buy0
- Hold11
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.62725.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.627 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.598 | 0.62 | +0.02 | +3.68% |
| May 6, 2026 | Mar 31, 2026 | 0.542 | 0.54 | 0.00 | -0.37% |
| Feb 4, 2026 | Dec 31, 2025 | 0.61 | 0.62 | +0.01 | +1.64% |
| Nov 4, 2025 | Sep 30, 2025 | 0.61 | 0.64 | +0.03 | +4.92% |
| Aug 5, 2025 | Jun 30, 2025 | 0.60 | 0.60 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Barclays | down | Overweight | Equal-Weight |
| Oct 26, 2026 | Citigroup | main | Neutral | Neutral |
| Oct 22, 2026 | JP Morgan | down | Overweight | Neutral |
| Oct 22, 2026 | Baird | main | Outperform | Outperform |
| Oct 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 6, 2026 | Barclays | up | Equal-Weight | Overweight |
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- Netherlands
- Website
- qiagen.com
News
- Do Options Traders Know Something About Qiagen Stock We Don't?
- Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ultralife Corporation (Nasdaq – ULBI), QIAGEN N.V. (NYSE – QGEN), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
- Barclays Downgrades Qiagen to Equal-Weight, Lowers Price Target to $53
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Enphase Energy, F5, Marvell Technology, MSG Rangers, Pentair, Silicon Motion Technology, Spotify Technology, Texas Instruments, Whirlpool, and More
- Citigroup Maintains Neutral on Qiagen, Raises Price Target to $52
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: QIAGEN N.V. (NYSE – QGEN), Varonis Systems, Inc. (Nasdaq – VRNS), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG)
- Long-Awaited Qiagen Buyout Closes At 15x EBITDA Multiple as Slow Growth Curbs Pricing
- This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
- This Qiagen Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Your note
Sign in to keep a note on QGEN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wellington Management Group, LLP | 6.02% | 12,406,763 | 624.49M | Jun 29, 2026 |
| Price (T.Rowe) Associates Inc | 5.51% | 11,354,379 | 571.52M | Jun 29, 2026 |
| Principal Financial Group, Inc. | 3.23% | 6,648,681 | 334.66M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.01% | 6,209,904 | 312.58M | Jun 29, 2026 |
| Blackrock Inc. | 2.87% | 5,905,678 | 297.26M | Jun 29, 2026 |
| Morgan Stanley | 2.45% | 5,042,391 | 253.81M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.93% | 6,045,368 | 304.29M | Jul 30, 2026 |
| TR PRICE-Price (T.Rowe) International Growth Equity Trust | 2.61% | 5,376,369 | 270.62M | Jun 29, 2026 |
| MFS Series Trust XVII-MFS International Equity Fund | 2.12% | 4,363,511 | 219.64M | Jun 29, 2026 |
| T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Intl Stock Fd. | 1.87% | 3,845,943 | 193.59M | Jul 30, 2026 |
| VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund | 1.47% | 3,037,846 | 152.91M | Jul 30, 2026 |
| MFS SERIES TRUST I-MFS Research International Fund | 1.23% | 2,526,121 | 127.15M | Aug 30, 2026 |